|
1
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valverde A, Bonhomme N, Farges O, Sauvanet
A, Flejou JF and Belghiti J: Resection of intrahepatic
cholangiocarcinoma: A Western experience. J Hepatobiliary Pancreat
Surg. 6:122–127. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Skipworth JR, Olde Damink SW, Imber C,
Bridgewater J, Pereira SP and Malagó M: Review article: Surgical,
neo-adjuvant and adjuvant management strategies in biliary tract
cancer. Aliment Pharmacol Ther. 34:1063–1078. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Macias R: Cholangiocarcinoma: Biology,
clinical management, and phamacological perspectives. ISRN Hematol.
2014:1–13. 2014.
|
|
5
|
Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP,
Sun JY, Wang TT, Xie J, He HR, Xing JF, et al: Establishment of
paclitaxel-resistant breast cancer cell line and nude mice models,
and underlying multidrug resistance mechanisms in vitro and in
vivo. Asian Pac J Cancer Prev. 14:6135–6140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Voutsadakis IA: Molecular predictors of
gemcitabine response in pancreatic cancer. World J Gastrointest
Oncol. 3:153–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hertel LW, Boder GB, Kroin JS, Rinzel SM,
Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor
activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer
Res. 50:4417–4422. 1990.PubMed/NCBI
|
|
8
|
Achiwa H, Oguri T, Sato S, Maeda H, Niimi
T and Ueda R: Determinants of sensitivity and resistance to
gemcitabine: The roles of human equilibrative nucleoside
transporter 1 and deoxycytidine kinase in non-small cell lung
cancer. Cancer Sci. 95:753–757. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Plunkett W, Huang P, Xu YZ, Heinemann V,
Grunewald R and Gandhi V: Gemcitabine: Metabolism, mechanisms of
action, and self-potentiation. Semin Oncol. 22(Suppl 11): S3–S10.
1995.
|
|
10
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
|
11
|
Davidson JD, Ma L, Flagella M, Geeganage
S, Gelbert LM and Slapak CA: An increase in the expression of
ribonucleotide reductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meli M, Tolomeo M, D’Alessandro N,
Grimaudo S, Notarbartolo M, Papoff G, Ruberti G, Rausa L and
Dusonchet L: Resistance to gemcitabine in a lymphoma cell line
resistant to Fas-mediated apoptosis. Anticancer Res. 24B:851–857.
2004.
|
|
13
|
Akada M, Crnogorac-Jurcevic T, Lattimore
S, Mahon P, Lopes R, Sunamura M, Matsuno S and Lemoine NR:
Intrinsic chemoresistance to gemcitabine is associated with
decreased expression of BNIP3 in pancreatic cancer. Clin Cancer
Res. 11:3094–3101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fulda S: Tumor resistance to apoptosis.
Int J Cancer. 124:511–515. 2009. View Article : Google Scholar
|
|
15
|
Shi X, Liu S, Kleeff J, Friess H and
Büchler MW: Acquired resistance of pancreatic cancer cells towards
5-Fluorouracil and gemcitabine is associated with altered
expression of apoptosis-regulating genes. Oncology. 62:354–362.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bergman AM, Pinedo HM and Peters GJ:
Determinants of resistance to 2′,2′-difluorodeoxycytidine
(gemcitabine). Drug Resist Updat. 5:19–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sato J, Kimura T, Saito T, Anazawa T,
Kenjo A, Sato Y, Tsuchiya T and Gotoh M: Gene expression analysis
for predicting gemcitabine resistance in human cholangiocarcinoma.
J Hepatobiliary Pancreat Sci. 18:700–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tepsiri N, Chaturat L, Sripa B, Namwat W,
Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity
and drug resistance profiles of human intrahepatic
cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Namwat N, Amimanan P, Loilome W,
Jearanaikoon P, Sripa B, Bhudhisawasdi V and Tassaneeyakul W:
Characterization of 5-fluorouracil-resistant cholangiocarcinoma
cell lines. Chemotherapy. 54:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thanasai J, Limpaiboon T, Jearanaikoon P,
Sripa B, Pairojkul C, Tantimavanich S and Miwa M: Effects of
thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil
sensitivity in cholangiocarcinoma. World J Gastroenterol.
16:1631–1638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Skehan P, Storeng R, Scudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Angelis PM, Kravik KL, Tunheim SH, Haug
T and Reichelt WH: Comparison of gene expression in HCT116
treatment derivatives generated by two different 5-fluorouracil
exposure protocols. Mol Cancer. 3:112004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yodkeeree S, Chaiwangyen W, Garbisa S and
Limtrakul P: Curcumin, demethoxycurcumin and bisdemethoxycurcumin
differentially inhibit cancer cell invasion through the
down-regulation of MMPs and uPA. J Nutr Biochem. 20:87–95. 2009.
View Article : Google Scholar
|
|
24
|
Zhang S, Furugawa T, Takahashi H, et al:
Analysis of gene expression in gemcitabine-resistant cells derived
from human pancreatic cancer cell. International Conference on
Human Health and Biomedical Engineering. 182–185. 2011.
|
|
25
|
Gerard CJ, Olsson K, Ramanathan R, Reading
C and Hanania EG: Improved quantitation of minimal residual disease
in multiple myeloma using real-time polymerase chain reaction and
plasmid-DNA complementarity determining region III standards.
Cancer Res. 58:3957–3964. 1998.PubMed/NCBI
|
|
26
|
Modok S, Mellor HR and Callaghan R:
Modulation of multidrug resistance efflux pump activity to overcome
chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zaman GJ, Flens MJ, van Leusden MR, de
Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F and
Broxterman HJ: The human multidrug resistance-associated protein
MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA.
91:8822–8826. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Courtois A, Payen L, Lagadic D, Guillouzo
A and Fardel O: Evidence for a multidrug resistance-associated
protein 1 (MRP1)-related transport system in cultured rat liver
biliary epithelial cells. Life Sci. 64:763–774. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: An emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
30
|
Smith L, Watson MB, O’Kane SL, Drew PJ,
Lind MJ and Cawkwell L: The analysis of doxorubicin resistance in
human breast cancer cells using antibody microarrays. Mol Cancer
Ther. 5:2115–2120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo X, Goessl E, Jin G, Collie-Duguid ES,
Cassidy J, Wang W and O’Brien V: Cell cycle perturbation and
acquired 5-fluorouracil chemoresistance. Anticancer Res. 28A:9–14.
2008.
|
|
32
|
Liu ZH, He YP, Zhou Y, Zhang P and Qin H:
Establishment and identification of the human multi-drug-resistant
cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep.
38:3075–3082. 2011. View Article : Google Scholar
|
|
33
|
Wu ZZ, Chien CM, Yang SH, Lin YH, Hu XW,
Lu YJ, Wu MJ and Lin SR: Induction of G2/M phase arrest and
apoptosis by a novel enediyne derivative, THDA, in chronic myeloid
leukemia (K562) cells. Mol Cell Biochem. 292:99–105. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reinke V and Lozano G: Differential
activation of p53 targets in cells treated with ultraviolet
radiation that undergo both apoptosis and growth arrest. Radiat
Res. 148:115–122. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siddik ZH, Mims B, Lozano G and Thai G:
Independent pathways of p53 induction by cisplatin and X-rays in a
cisplatin-resistant ovarian tumor cell line. Cancer Res.
58:698–703. 1998.PubMed/NCBI
|
|
36
|
Strasser A, Puthalakath H, O’Reilly LA and
Bouillet P: What do we know about the mechanisms of elimination of
autoreactive T and B cells and what challenges remain. Immunol Cell
Biol. 86:57–66. 2008. View Article : Google Scholar
|
|
37
|
Ramp U, Dejosez M, Mahotka C, Czarnotta B,
Kalinski T, Wenzel M, Lorenz I, Müller M, Krammer P, Gabbert HE, et
al: Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: A
potential factor of multidrug resistance in human renal cell
carcinoma. Br J Cancer. 82:1851–1859. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang Y, Meleady P, Cleary I, McDonnell S,
Connolly L and Clynes M: Selection with melphalan or paclitaxel
(Taxol) yields variants with different patterns of multidrug
resistance, integrin expression and in vitro invasiveness. Eur J
Cancer. 37:1041–1052. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang Y, McDonnell S and Clynes M:
Examining the relationship between cancer invasion/metastasis and
drug resistance. Curr Cancer Drug Targets. 2:257–277. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zahreddine H and Borden KL: Mechanisms and
insights into drug resistance in cancer. Front Pharmacol. 4:282013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hazlehurst LA, Argilagos RF and Dalton WS:
Beta1 integrin mediated adhesion increases Bim protein degradation
and contributes to drug resistance in leukaemia cells. Br J
Haematol. 136:269–275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lwin T, Hazlehurst LA, Dessureault S, Lai
R, Bai W, Sotomayor E, Moscinski LC, Dalton WS and Tao J: Cell
adhesion induces p27Kip1-associated cell-cycle arrest through
down-regulation of the SCFSkp2 ubiquitin ligase pathway in
mantle-cell and other non-Hodgkin B-cell lymphomas. Blood.
110:1631–1638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Goel HL and Dey CS: Role of protein kinase
C during insulin mediated skeletal muscle cell spreading. J Muscle
Res Cell Motil. 23:269–277. 2002. View Article : Google Scholar
|
|
45
|
Kang J: Protein kinase C (PKC) isozymes
and cancer. New J Sci. 36:20142014.
|
|
46
|
Liao CH, Sang S, Ho CT and Lin JK:
Garcinol modulates tyrosine phosphorylation of FAK and subsequently
induces apoptosis through down-regulation of Src, ERK, and Akt
survival signaling in human colon cancer cells. J Cell Biochem.
96:155–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Perkins ND: The Rel/NF-kappa B family:
Friend and foe. Trends Biochem Sci. 25:434–440. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ghosh S and Karin M: Missing pieces in the
NF-kappaB puzzle. Cell. 109(Suppl): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Matsumoto K, Nagahara T, Okano J and
Murawaki Y: The growth inhibition of hepatocellular and
cholangiocellular carcinoma cells by gemcitabine and the roles of
extracellular signal-regulated and checkpoint kinases. Oncol Rep.
20:863–872. 2008.PubMed/NCBI
|
|
50
|
Yoon H, Min JK, Lee JW, Kim DG and Hong
HJ: Acquisition of chemoresistance in intrahepatic
cholangiocarcinoma cells by activation of AKT and extracellular
signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun.
405:333–337. 2011. View Article : Google Scholar
|
